Blog
RSS FeedPosted by Michael Wonder on 07 Feb 2019
Vertex fears its triplet will also face UK reimbursement battle
6 February 2019 - Vertex Pharmaceuticals' cystic fibrosis business grew more than 40% in 2018, partially because of reimbursement victories in ...
Posted by Michael Wonder on 06 Feb 2019
NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
6 February 2019 - NICE and the Canadian Agency for Drugs and Technology in Health have launched a new collaboration to ...
Posted by Michael Wonder on 04 Feb 2019
UK patient activist group takes aim at Orkambi patent
4 February 2019 - Calls to bypass patent adds to pressure on Vertex. ...
Posted by Michael Wonder on 04 Feb 2019
Mother of four is denied cancer drug that could save her life
2 February 2019 - A British nurse with four children is being denied potentially life-saving cancer treatment that was approved ...
Posted by Michael Wonder on 04 Feb 2019
Calls for action on patients denied £100,000 cystic fibrosis drug
4 February 2019 - Ministers urged to consider revoking patent on life-extending Orkambi, which NHS cannot afford. ...
Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...
Posted by Michael Wonder on 31 Jan 2019
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
31 January 2019 - Members of parliament aim to break three year deadlock. ...
Posted by Michael Wonder on 29 Jan 2019
Novartis urges government to ‘minimise disruption’ in no-deal Brexit
28 January 2019 - Novartis has issued a statement expressing concern over the state of medicine supply to the UK, ...
Posted by Michael Wonder on 29 Jan 2019
NICE Scientific Advice launches collaborative programme with life sciences industry body
29 January 2019 - NICE has announced a collaboration with the body which represents life sciences organisations in the UK. ...
Posted by Michael Wonder on 28 Jan 2019
Cystic fibrosis patients lobby Vertex to drop drug prices
28 January 2019 - Healthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to ...
Posted by Michael Wonder on 28 Jan 2019
Lords continue to call for clarity on ‘no-deal Brexit’ medicines access
28 January 2019 - As uncertainty remains on access to medicine in the event of a no-deal Brexit, Lords are ...
Posted by Michael Wonder on 23 Jan 2019
Discrete choice experiments in health economics: past, present and future
23 January 2019 - Discrete choice experiments are increasingly advocated as a way to quantify preferences for health. ...
Posted by Michael Wonder on 23 Jan 2019
Vertex’s CF drug gets label extension as pricing row continues Vertex’s CF drug gets label extension as pricing row continues
23 January 2019 - While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug ...
Posted by Michael Wonder on 23 Jan 2019
Future costs in cost-effectiveness analyses: past, present, future
23 January 2019 - There has been considerable debate on the extent to which future costs should be included in cost-effectiveness ...
Posted by Michael Wonder on 21 Jan 2019
NHS England sees off AbbVie's hepatitis C legal challenge
21 January 2019 - Claims of unfair process dismissed by High Court. ...